An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Acronyms SHINE
- Sponsors Biogen; Ionis Pharmaceuticals
- 19 Dec 2017 Planned number of patients changed from 289 to 292.
- 19 Dec 2017 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 19 Dec 2017 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.